Can patients with lung adenocarcinoma who develop drug resistance after taking osimertinib still undergo genetic testing?

To the question of whether patients with lung adenocarcinoma who develop drug resistance after taking osimertinib can still undergo genetic testing, the answer is yes. Genetic testing plays a crucial role in the treatment of patients with lung adenocarcinoma, especially after drug resistance.

Genetic testing is the basis for precise treatment of patients with lung adenocarcinoma. By detecting specific genetic variants in tumor tissue or blood samples, doctors can choose the most appropriate targeted therapy for their patients. After osimertinib resistance, genetic testing can help discover new mutation targets, thereby guiding the formulation of subsequent treatment plans.

After resistance to osimertinib, the specific cause of resistance can be clarified through genetic testing. For example, secondary mutations in the EGFR gene (such as C797S mutation) or mutations in other genes (such as METamplification, HER2amplification, etc.) may lead to drug resistance. Understanding these resistance mechanisms can help doctors choose more effective treatments for their patients.

When tissue samples are unavailable, blood samples become an effective alternative. Through blood genetic testing, circulating tumor DNA (ctDNA) can be detected, thus reflecting the genetic mutation of the tumor. This method is non-invasive, convenient, and in some cases highly accurate.

Based on the results of genetic testing, doctors can develop personalized follow-up treatment plans for patients. For example, targeting specific gene mutations, select corresponding targeted drugs or combination treatment options to improve the therapeutic effect.

In actual clinical cases, some patients discovered new mutation targets through genetic testing after becoming resistant to osimertinib, and successfully switched to other targeted drugs or combination treatments, achieving effective disease control. In addition, multiple studies have also confirmed the important role of genetic testing in guiding treatment of patients with lung adenocarcinoma after drug resistance.